CytomX Therapeutics, Inc. (CTMX)
CTMX Stock Price Chart
Explore CytomX Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CTMX price movements and trends.
CTMX Company Profile
Discover essential business fundamentals and corporate details for CytomX Therapeutics, Inc. (CTMX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2015
Employees
119.00
Website
https://www.cytomx.comCEO
Sean A. McCarthy
Description
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
CTMX Financial Timeline
Browse a chronological timeline of CytomX Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.11, while revenue estimate is $12.39m.
Earnings released on 7 May 2026
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $10.26m , beating expectations by +119.08%.
Earnings released on 16 Mar 2026
EPS came in at -$0.22 falling short of the estimated -$0.08 by -175.00%, while revenue for the quarter reached $661.00k , missing expectations by -90.98%.
Earnings released on 6 Nov 2025
EPS came in at -$0.09 falling short of the estimated -$0.05 by -82.52%, while revenue for the quarter reached $5.96m , missing expectations by -18.59%.
Earnings released on 7 Aug 2025
EPS came in at -$0.00 surpassing the estimated -$0.06 by +98.11%, while revenue for the quarter reached $18.66m , beating expectations by +2.07%.
Earnings released on 12 May 2025
EPS came in at $0.27 surpassing the estimated $0.12 by +116.35%, while revenue for the quarter reached $50.92m , beating expectations by +43.74%.
Earnings released on 6 Mar 2025
EPS came in at $0.22 surpassing the estimated -$0.23 by +195.65%, while revenue for the quarter reached $38.09m , beating expectations by +192.12%.
Earnings released on 7 Nov 2024
EPS came in at $0.07 surpassing the estimated -$0.17 by +141.18%, while revenue for the quarter reached $33.43m , beating expectations by +147.03%.
Earnings released on 8 Aug 2024
EPS came in at -$0.08 surpassing the estimated -$0.14 by +42.86%, while revenue for the quarter reached $25.12m , beating expectations by +25.64%.
Earnings released on 8 May 2024
EPS came in at $0.17 surpassing the estimated -$0.08 by +312.50%, while revenue for the quarter reached $41.46m , beating expectations by +93.48%.
Earnings released on 11 Mar 2024
EPS came in at $0.01 surpassing the estimated $0.00 by +134.74%, while revenue for the quarter reached $26.61m , beating expectations by +26.46%.
Earnings released on 7 Nov 2023
EPS came in at $0.04 surpassing the estimated -$0.19 by +121.05%, while revenue for the quarter reached $26.38m , beating expectations by +29.27%.
Earnings released on 8 Aug 2023
EPS came in at -$0.02 surpassing the estimated -$0.20 by +90.00%, while revenue for the quarter reached $24.72m , beating expectations by +78.13%.
Earnings released on 9 May 2023
EPS came in at -$0.05 surpassing the estimated -$0.11 by +54.88%, while revenue for the quarter reached $23.50m , beating expectations by +19.95%.
Earnings released on 27 Mar 2023
EPS came in at -$0.43 falling short of the estimated -$0.24 by -79.17%, while revenue for the quarter reached $20.12m , beating expectations by +12.73%.
Earnings released on 8 Nov 2022
EPS came in at -$0.35 falling short of the estimated -$0.31 by -12.90%, while revenue for the quarter reached $11.15m , missing expectations by -38.59%.
Earnings released on 4 Aug 2022
EPS came in at -$0.37 falling short of the estimated -$0.36 by -2.78%, while revenue for the quarter reached $12.85m , missing expectations by -29.05%.
Earnings released on 5 May 2022
EPS came in at -$0.37 falling short of the estimated -$0.36 by -2.78%, while revenue for the quarter reached $9.04m , missing expectations by -57.45%.
Earnings released on 1 Mar 2022
EPS came in at -$0.40 falling short of the estimated -$0.28 by -42.86%, while revenue for the quarter reached $19.73m , beating expectations by +0.78%.
Earnings released on 4 Nov 2021
EPS came in at -$0.35 falling short of the estimated -$0.31 by -12.90%, while revenue for the quarter reached $17.59m , beating expectations by +1.02%.
Earnings released on 5 Aug 2021
EPS came in at -$0.30 surpassing the estimated -$0.32 by +6.25%, while revenue for the quarter reached $16.29m , meeting expectations.
CTMX Stock Performance
Access detailed CTMX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
